BACKGROUND/AIMS: Several shortcomings have limited the routine use of autogenous vascularized bone graft. The present study investigates the prefabrication of vascularized scaffold with the desired shape and microarchitecture combined with recombinant human vascular endothelial growth factor 165 (rhVEGF(165)) to mimic autogenous vascularized bone graft. METHODS: Eighty-five porous calcium phosphate cement scaffolds constructed by rapid prototyping technology were divided into four groups: group A [rhVEGF(165)-fibrin sealant (FS) scaffold], group B (hVEGF(165) scaffold), group C (FS scaffold), and group D (scaffold alone). The release of rhVEGF(165) from the scaffolds was examined in vitro. The vessel density, relative functionalized vessels, vessel diameter and relative vessel area were also measured. RESULTS: The sustained release of hVEGF(165) lasted 14 days in the absence of plasmin and 12 days in the presence of plasmin in group A and 10 days in group B. There was no statistical difference between groups A and B at 2 or 4 weeks in terms of vessel density, relative functionalized vessels, vessel diameter, and relative vessel area, as between groups C and D. However, the above parameters were greater in groups A and B than groups C and D. CONCLUSION: The scaffolds with the desired shape and microarchitecture combined with rhVEGF(165) could shorten the time needed for the construction of prefabricated vascularized grafts and accelerate the maturation of the vessels. 2008 S. Karger AG, Basel.
BACKGROUND/AIMS: Several shortcomings have limited the routine use of autogenous vascularized bone graft. The present study investigates the prefabrication of vascularized scaffold with the desired shape and microarchitecture combined with recombinant human vascular endothelial growth factor 165 (rhVEGF(165)) to mimic autogenous vascularized bone graft. METHODS: Eighty-five porous calcium phosphate cement scaffolds constructed by rapid prototyping technology were divided into four groups: group A [rhVEGF(165)-fibrin sealant (FS) scaffold], group B (hVEGF(165) scaffold), group C (FS scaffold), and group D (scaffold alone). The release of rhVEGF(165) from the scaffolds was examined in vitro. The vessel density, relative functionalized vessels, vessel diameter and relative vessel area were also measured. RESULTS: The sustained release of hVEGF(165) lasted 14 days in the absence of plasmin and 12 days in the presence of plasmin in group A and 10 days in group B. There was no statistical difference between groups A and B at 2 or 4 weeks in terms of vessel density, relative functionalized vessels, vessel diameter, and relative vessel area, as between groups C and D. However, the above parameters were greater in groups A and B than groups C and D. CONCLUSION: The scaffolds with the desired shape and microarchitecture combined with rhVEGF(165) could shorten the time needed for the construction of prefabricated vascularized grafts and accelerate the maturation of the vessels. 2008 S. Karger AG, Basel.
Authors: Mousumi Sukul; Thuy Ba Linh Nguyen; Young-Ki Min; Sun-Young Lee; Byong-Taek Lee Journal: Tissue Eng Part A Date: 2015-04-29 Impact factor: 3.845